Regulation and function of DNA and histone methylations

Current Pharmaceutical Design

Volumn 19, Issue 4, 2013, Pages 719-733

  Ferrari, Karin Johanna ^a   Pasini, Diego ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Chromatin modifications; DNA methylation; Epigenetics; Histone methylation

Indexed keywords

ADENOSYLHOMOCYSTEINASE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; HISTONE; HISTONE H2A; HISTONE H2B; HISTONE H3; HISTONE H4; RNA POLYMERASE II; S ADENOSYLMETHIONINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AUTONOMIC NEUROPATHY; BLADDER CARCINOMA; BREAST CANCER; BREAST CARCINOMA; CENTROMERE; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOMAL INSTABILITY; COLON CANCER; COLORECTAL CANCER; COLORECTAL CARCINOMA; CPG ISLAND; DEGENERATIVE DISEASE; DNA METHYLATION; EMBRYONIC STEM CELL; ENZYME ACTIVITY; ESOPHAGUS CARCINOMA; FACE MALFORMATION; FIBROBLAST; GLIOBLASTOMA; HISTONE METHYLATION; HISTONE UBIQUITINATION; HODGKIN DISEASE; HUMAN; HUNTINGTON CHOREA; HYDROXYLATION; IMMUNE DEFICIENCY; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CANCER; LIVER CELL CARCINOMA; LOSS OF FUNCTION MUTATION; LUNG CANCER; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MISSENSE MUTATION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DNA BINDING; REVIEW; SOTOS SYNDROME; TRANSCRIPTION REGULATION; UPREGULATION; UTERINE CERVIX CARCINOMA;

EID: 84876697723     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213804581990     Document Type: Review

References (280)

1. Guertin MJ, Lis JT. Chromatin landscape dictates HSF binding to target DNA elements. PLoS genetics 2010; 6.
2. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293: 1074-80.
3. Luger K. Structure and dynamic behavior of nucleosomes. Curr Opin Genet Dev 2003; 13: 127-35.
4. Lee JT. Gracefully ageing at 50, X-chromosome inactivation becomes a paradigm for RNA and chromatin control. Nature reviews. Molecular cell biology 2011; 12: 815-26.
5. Delaval K, Feil R. Epigenetic regulation of mammalian genomic imprinting. Current opinion in genetics & development 2004; 14: 188-95.
6. Fullgrabe J, Kavanagh E, Joseph B. Histone onco-modifications. Oncogene 2011; 30: 3391-403.
7. Smith BC, Denu JM. Chemical mechanisms of histone lysine and arginine modifications. Biochimica et biophysica acta 2009; 1789: 45-57.
8. Cheng X. DNA modification by methyltransferases. Current opinion in structural biology 1995; 5: 4-10.
9. Chiacchiera F, Piunti A, Pasini D. Epigenetic Methylations and their Connections with Metabolism. Cellular and Molecular Life Sciences, in press.
10. Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annual review of biochemistry 2005; 74: 481-514.
11. Goll MG, Kirpekar F, Maggert KA, et al. Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2. Science 2006; 311: 395-8.
12. Pradhan S, Bacolla A, Wells RD, Roberts RJ. Recombinant human DNA (cytosine-5) methyltransferase. I. Expression, purification, and comparison of de novo and maintenance methylation. The Journal of biological chemistry 1999; 274: 33002-10.
13. Kim GD, Ni J, Kelesoglu N, Roberts RJ, Pradhan S. Co-operation and communication between the human maintenance and de novo DNA (cytosine-5) methyltransferases. The EMBO journal 2002; 21: 4183-95.
14. Chen T, Ueda Y, Dodge JE, Wang Z, Li E. Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. Molecular and cellular biology 2003; 23: 5594-605.
15. Bostick M, Kim JK, Esteve PO, Clark A, Pradhan S, Jacobsen SE. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 2007; 317: 1760-4.
16. Chuang LS, Ian HI, Koh TW, Ng HH, Xu G, Li BF. Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1. Science 1997; 277: 1996-2000.
17. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999; 99: 247-57.
18. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nature reviews. Genetics 2008; 9: 465-76.
19. Weber M, Schubeler D. Genomic patterns of DNA methylation: targets and function of an epigenetic mark. Current opinion in cell biology 2007; 19: 273-80.
20. Ballestar E, Wolffe AP. Methyl-CpG-binding proteins. Targeting specific gene repression. European journal of biochemistry / FEBS 2001; 268: 1-6.
21. Lister R, Pelizzola M, Dowen RH, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009; 462: 315-22.
22. Stadler MB, Murr R, Burger L, et al. DNA-binding factors shape the mouse methylome at distal regulatory regions. Nature 2011; 480: 490-5.
23. Chen T, Hevi S, Gay F, et al. Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells. Nature genetics 2007; 39: 391-6.
24. Lei H, Oh SP, Okano M, et al. De novo DNA cytosine methyltransferase activities in mouse embryonic stem cells. Development 1996; 122: 3195-205.
25. Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992; 69: 915-26.
26. Kaneda M, Okano M, Hata K, et al. Essential role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting. Nature 2004; 429: 900-3.
27. Chen ZX, Mann JR, Hsieh CL, Riggs AD, Chedin F. Physical and functional interactions between the human DNMT3L protein and members of the de novo methyltransferase family. Journal of cellular biochemistry 2005; 95: 902-17.
28. Gowher H, Liebert K, Hermann A, Xu G, Jeltsch A. Mechanism of stimulation of catalytic activity of Dnmt3A and Dnmt3B DNA-(cytosine-C5)-methyltransferases by Dnmt3L. The Journal of biological chemistry 2005; 280: 13341-8.
29. Chedin F, Lieber MR, Hsieh CL. The DNA methyltransferase-like protein DNMT3L stimulates de novo methylation by Dnmt3a. Proceedings of the National Academy of Sciences of the United States of America 2002; 99: 16916-21.
30. Suetake I, Shinozaki F, Miyagawa J, Takeshima H, Tajima S. DNMT3L stimulates the DNA methylation activity of Dnmt3a and Dnmt3b through a direct interaction. The Journal of biological chemistry 2004; 279: 27816-23.
31. Bourc'his D, Xu GL, Lin CS, Bollman B, Bestor TH. Dnmt3L and the establishment of maternal genomic imprints. Science 2001; 294: 2536-9.
32. Klein CJ, Botuyan MV, Wu Y, et al. Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. Nature genetics 2011; 43: 595-600.
33. Xu GL, Bestor TH, Bourc'his D, et al. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 1999; 402: 187-91.
34. Walter MJ, Ding L, Shen D, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U. K 2011; 25: 1153-8.
35. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. The New England journal of medicine 2010; 363: 2424-33.
36. Agger K, Christensen J, Cloos PA, Helin K. The emerging functions of histone demethylases. Current opinion in genetics & development 2008; 18: 159-68.
37. Bhattacharya SK, Ramchandani S, Cervoni N, Szyf M. A mammalian protein with specific demethylase activity for mCpG DNA. Nature 1999; 397: 579-83.
38. Mayer W, Niveleau A, Walter J, Fundele R, Haaf T. Demethylation of the zygotic paternal genome. Nature 2000; 403: 501-2.
39. Oswald J, Engemann S, Lane N, et al. Active demethylation of the paternal genome in the mouse zygote. Current biology: CB 2000; 10: 475-8.
40. Sasaki H, Matsui Y. Epigenetic events in mammalian germ-cell development: reprogramming and beyond. Nature reviews. Genetics 2008; 9: 129-40.
41. Zhu JK. Active DNA demethylation mediated by DNA glycosylases. Annual review of genetics 2009; 43: 143-66.
42. Branzei D, Foiani M. Regulation of DNA repair throughout the cell cycle. Nature reviews. Molecular cell biology 2008; 9: 297-308.
43. Cortellino S, Xu J, Sannai M, et al. Thymine DNA glycosylase is essential for active DNA demethylation by linked deaminationbase excision repair. Cell 2011; 146: 67-79.
44. Maiti A, Drohat AC. Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: potential implications for active demethylation of CpG sites. The Journal of biological chemistry 2011; 286: 35334-8.
45. He YF, Li BZ, Li Z, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011; 333: 1303-7.
46. Ito S, Shen L, Dai Q, et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011; 333: 1300-3.
47. Wu H, Zhang Y. Mechanisms and functions of Tet proteinmediated 5-methylcytosine oxidation. Genes & development 2011; 25: 2436-52.
48. Williams K, Christensen J, Helin K. DNA methylation: TET proteins-guardians of CpG islands? EMBO reports 2011; 13: 28-35.
49. Wu H, D'Alessio AC, Ito S, et al. Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells. Genes & development 2011; 25: 679-84.
50. Ku CS, Naidoo N, Wu M, Soong R. Studying the epigenome using next generation sequencing. Journal of medical genetics 2011; 48: 721-30.
51. Szulwach KE, Li X, Li Y, et al. Integrating 5-hydroxymethylcytosine into the epigenomic landscape of human embryonic stem cells. PLoS genetics 2011; 7: e1002154.
52. Stroud H, Feng S, Morey Kinney S, Pradhan S, Jacobsen SE. 5-Hydroxymethylcytosine is associated with enhancers and gene bodies in human embryonic stem cells. Genome biology 2011; 12: R54.
53. Koh KP, Yabuuchi A, Rao S, et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell stem cell 2011; 8: 200-13.
54. Dawlaty MM, Ganz K, Powell BE, et al. Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development. Cell stem cell 2011; 9: 166-75.
55. Ono R, Taki T, Taketani T, Taniwaki M, Kobayashi H, Hayashi Y. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer research 2002; 62: 4075-80.
56. Lorsbach RB, Moore J, Mathew S, Raimondi SC, Mukatira ST, Downing JR. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 2003; 17: 637-41.
57. Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010; 468: 839-43.
58. Cimmino L, Abdel-Wahab O, Levine RL, Aifantis I. TET family proteins and their role in stem cell differentiation and transformation. Cell stem cell 2011; 9: 193-204.
59. Kudo Y, Tateishi K, Yamamoto K, et al. Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer science 2012; 103: 670-6.
60. Inoue A, Zhang Y. Replication-dependent loss of 5-hydroxymethylcytosine in mouse preimplantation embryos. Science 2011; 334: 194.
61. Gu TP, Guo F, Yang H, et al. The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature 2011; 477: 606-10.
62. Wossidlo M, Nakamura T, Lepikhov K, et al. 5-Hydroxymethylcytosine in the mammalian zygote is linked with epigenetic reprogramming. Nature communications 2011; 2: 241.
63. Iqbal K, Jin SG, Pfeifer GP, Szabo PE. Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine. Proceedings of the National Academy of Sciences of the United States of America 2011; 108: 3642-7.
64. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997; 389: 251-60.
65. Berger SL. The complex language of chromatin regulation during transcription. Nature 2007; 447: 407-12.
66. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705.
67. Turner BM. Histone acetylation and an epigenetic code. BioEssays: news and reviews in molecular, cellular and developmental biology 2000; 22: 836-45.
68. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000; 403: 41-5.
69. Hublitz P, Albert M, Peters AH. Mechanisms of transcriptional repression by histone lysine methylation. The International journal of developmental biology 2009; 53: 335-54.
70. Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nature reviews. Molecular cell biology 2005; 6: 838-49.
71. Bannister AJ, Schneider R, Kouzarides T. Histone methylation: dynamic or static? Cell 2002; 109: 801-6.
72. Singer MS, Kahana A, Wolf AJ, et al. Identification of high-copy disruptors of telomeric silencing in Saccharomyces cerevisiae. Genetics 1998; 150: 613-32.
73. Feng Q, Wang H, Ng HH, et al. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Current biology: CB 2002; 12: 1052-8.
74. Lacoste N, Utley RT, Hunter JM, Poirier GG, Cote J. Disruptor of telomeric silencing-1 is a chromatin-specific histone H3 methyltransferase. The Journal of biological chemistry 2002; 277: 30421-4.
75. van Leeuwen F, Gafken PR, Gottschling DE. Dot1p modulates silencing in yeast by methylation of the nucleosome core. Cell 2002; 109: 745-56.
76. Ng HH, Feng Q, Wang H, et al. Lysine methylation within the globular domain of histone H3 by Dot1 is important for telomeric silencing and Sir protein association. Genes & development 2002; 16: 1518-27.
77. Nguyen AT, Zhang Y. The diverse functions of Dot1 and H3K79 methylation. Genes & development 2011; 25: 1345-58.
78. Green EM, Antczak AJ, Bailey AO, et al. Replication-independent histone deposition by the HIR complex and Asf1. Current biology: CB 2005; 15: 2044-9.
79. Silva AC, Xu X, Kim HS, et al. The replication-independent histone H3-H4 chaperones HIR, ASF1, and RTT106 co-operate to maintain promoter fidelity. Journal of biological chemistry 2012; 287: 1709-18.
80. Santos-Rosa H, Kirmizis A, Nelson C, et al. Histone H3 tail clipping regulates gene expression. Nature structural & molecular biology 2009; 16: 17-22.
81. Cuthbert GL, Daujat S, Snowden AW, et al. Histone deimination antagonizes arginine methylation. Cell 2004; 118: 545-53.
82. Wang Y, Wysocka J, Sayegh J, et al. Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 2004; 306: 279-83.
83. Pedersen MT, Helin K. Histone demethylases in development and disease. Trends in cell biology 2010; 20: 662-71.
84. Klose RJ, Zhang Y. Regulation of histone methylation by demethylimination and demethylation. Nature reviews. Molecular cell biology 2007; 8: 307-18.
85. Sikorski TW, Buratowski S. The basal initiation machinery: beyond the general transcription factors. Current opinion in cell biology 2009; 21: 344-51.
86. Selth LA, Sigurdsson S, Svejstrup JQ. Transcript Elongation by RNA Polymerase II. Annual review of biochemistry 2010; 79: 271-93.
87. Lykke-Andersen S, Jensen TH. Overlapping pathways dictate termination of RNA polymerase II transcription. Biochimie 2007; 89: 1177-82.
88. Buratowski S. Progression through the RNA polymerase II CTD cycle. Molecular cell 2009; 36: 541-6.
89. Komarnitsky P, Cho EJ, Buratowski S. Different phosphorylated forms of RNA polymerase II and associated mRNA processing factors during transcription. Genes & development 2000; 14: 2452-60.
90. Keogh MC, Podolny V, Buratowski S. Bur1 kinase is required for efficient transcription elongation by RNA polymerase II. Molecular and cellular biology 2003; 23: 7005-18.
91. Patturajan M, Conrad NK, Bregman DB, Corden JL. Yeast carboxyl-terminal domain kinase I positively and negatively regulates RNA polymerase II carboxyl-terminal domain phosphorylation. The Journal of biological chemistry 1999; 274: 27823-8.
92. Fabrega C, Shen V, Shuman S, Lima CD. Structure of an mRNA capping enzyme bound to the phosphorylated carboxy-terminal domain of RNA polymerase II. Molecular cell 2003; 11: 1549-61.
93. Ng HH, Robert F, Young RA, Struhl K. Targeted recruitment of Set1 histone methylase by elongating Pol II provides a localized mark and memory of recent transcriptional activity. Molecular cell 2003; 11: 709-19.
94. Ahn SH, Kim M, Buratowski S. Phosphorylation of serine 2 within the RNA polymerase II C-terminal domain couples transcription and 3' end processing. Molecular cell 2004; 13: 67-76.
95. Ni Z, Schwartz BE, Werner J, Suarez JR, Lis JT. Coordination of transcription, RNA processing, and surveillance by P-TEFb kinase on heat shock genes. Molecular cell 2004; 13: 55-65.
96. Krogan NJ, Kim M, Tong A, et al. Methylation of histone H3 by Set2 in Saccharomyces cerevisiae is linked to transcriptional elongation by RNA polymerase II. Molecular and cellular biology 2003; 23: 4207-18.
97. Schaft D, Roguev A, Kotovic KM, et al. The histone 3 lysine 36 methyltransferase, SET2, is involved in transcriptional elongation. Nucleic acids research 2003; 31: 2475-82.
98. Xiao T, Hall H, Kizer KO, et al. Phosphorylation of RNA polymerase II CTD regulates H3 methylation in yeast. Genes & development 2003; 17: 654-63.
99. Li B, Howe L, Anderson S, Yates JR, 3rd, Workman JL. The Set2 histone methyltransferase functions through the phosphorylated carboxyl-terminal domain of RNA polymerase II. The Journal of biological chemistry 2003; 278: 8897-903.
100. Taverna SD, Ilin S, Rogers RS, et al. Yng1 PHD finger binding to H3 trimethylated at K4 promotes NuA3 HAT activity at K14 of H3 and transcription at a subset of targeted ORFs. Molecular cell 2006; 24: 785-96.
101. Martin DG, Baetz K, Shi X, et al. The Yng1p plant homeodomain finger is a methyl-histone binding module that recognizes lysine 4-methylated histone H3. Molecular and cellular biology 2006; 26: 7871-9.
102. Govind CK, Qiu H, Ginsburg DS, et al. Phosphorylated Pol II CTD recruits multiple HDACs, including Rpd3C(S), for methylationdependent deacetylation of ORF nucleosomes. Molecular cell 2010; 39: 234-46.
103. Kim T, Buratowski S. Dimethylation of H3K4 by Set1 recruits the Set3 histone deacetylase complex to 5' transcribed regions. Cell 2009; 137: 259-72.
104. Li B, Jackson J, Simon MD, et al. Histone H3 lysine 36 dimethylation (H3K36me2) is sufficient to recruit the Rpd3s histone deacetylase complex and to repress spurious transcription. The Journal of biological chemistry 2009; 284: 7970-6.
105. Li B, Gogol M, Carey M, Lee D, Seidel C, Workman JL. Combined action of PHD and chromo domains directs the Rpd3S HDAC to transcribed chromatin. Science 2007; 316: 1050-4.
106. Keogh MC, Kurdistani SK, Morris SA, et al. Cotranscriptional set2 methylation of histone H3 lysine 36 recruits a repressive Rpd3 complex. Cell 2005; 123: 593-605.
107. Carrozza MJ, Li B, Florens L, et al. Histone H3 methylation by Set2 directs deacetylation of coding regions by Rpd3S to suppress spurious intragenic transcription. Cell 2005; 123: 581-92.
108. Ruthenburg AJ, Allis CD, Wysocka J. Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Molecular cell 2007; 25: 15-30.
109. Shilatifard A. Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation. Current opinion in cell biology 2008; 20: 341-8.
110. Rada-Iglesias A, Bajpai R, Swigut T, Brugmann SA, Flynn RA, Wysocka J. A unique chromatin signature uncovers early developmental enhancers in humans. Nature 2011; 470: 279-83.
111. Creyghton MP, Cheng AW, Welstead GG, et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 21931-6.
112. Visel A, Blow MJ, Li Z, et al. ChIP-seq accurately predicts tissuespecific activity of enhancers. Nature 2009; 457: 854-8.
113. Heintzman ND, Stuart RK, Hon G, et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nature genetics 2007; 39: 311-8.
114. Pokholok DK, Harbison CT, Levine S, et al. Genome-wide map of nucleosome acetylation and methylation in yeast. Cell 2005; 122: 517-27.
115. Liu CL, Kaplan T, Kim M, et al. Single-nucleosome mapping of histone modifications in S. cerevisiae. PLoS biology 2005; 3: e328.
116. Otani J, Nankumo T, Arita K, Inamoto S, Ariyoshi M, Shirakawa M. Structural basis for recognition of H3K4 methylation status by the DNA methyltransferase 3A ATRX-DNMT3-DNMT3L domain. EMBO reports 2009; 10: 1235-41.
117. Ooi SK, Qiu C, Bernstein E, et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 2007; 448: 714-7.
118. Hu JL, Zhou BO, Zhang RR, Zhang KL, Zhou JQ, Xu GL. The Nterminus of histone H3 is required for de novo DNA methylation in chromatin. Proceedings of the National Academy of Sciences of the United States of America 2009; 106: 22187-92.
119. Meissner A, Mikkelsen TS, Gu H, et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 2008; 454: 766-70.
120. Weber M, Hellmann I, Stadler MB, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nature genetics 2007; 39: 457-66.
121. Christensen J, Agger K, Cloos PA, et al. RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3. Cell 2007; 128: 1063-76.
122. Ellinger J, Kahl P, Mertens C, et al. Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. International journal of cancer. Journal international du cancer 2010; 127: 2360-6.
123. Manuyakorn A, Paulus R, Farrell J, et al. Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2010; 28: 1358-65.
124. Elsheikh SE, Green AR, Rakha EA, et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer research 2009; 69: 3802-9.
125. Barlesi F, Giaccone G, Gallegos-Ruiz MI, et al. Global histone modifications predict prognosis of resected non small-cell lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2007; 25: 4358-64.
126. Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005; 435: 1262-6.
127. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nature reviews. Cancer 2007; 7: 823-33.
128. Liu H, Cheng EH, Hsieh JJ. MLL fusions: pathways to leukemia. Cancer biology & therapy 2009; 8: 1204-11.
129. Hayami S, Kelly JD, Cho HS, et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. International journal of cancer. Journal international du cancer 2011; 128: 574-86.
130. Schulte JH, Lim S, Schramm A, et al. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer research 2009; 69: 2065-71.
131. Edmunds JW, Mahadevan LC, Clayton AL. Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation. The EMBO journal 2008; 27: 406-20.
132. Rega S, Stiewe T, Chang DI, et al. Identification of the full-length huntingtin-interacting protein p231HBP/HYPB as a DNA-binding factor. Molecular and cellular neurosciences 2001; 18: 68-79.
133. Faber PW, Barnes GT, Srinidhi J, Chen J, Gusella JF, MacDonald ME. Huntingtin interacts with a family of WW domain proteins. Human molecular genetics 1998; 7: 1463-74.
134. Mao M, Fu G, Wu JS, et al. Identification of genes expressed in human CD34(+) hematopoietic stem/progenitor cells by expressed sequence tags and efficient full-length cDNA cloning. Proceedings of the National Academy of Sciences of the United States of America 1998; 95: 8175-80.
135. Miremadi A, Oestergaard MZ, Pharoah PD, Caldas C. Cancer genetics of epigenetic genes. Human molecular genetics 2007; 16 Spec No 1: R28-49.
136. Rayasam GV, Wendling O, Angrand PO, et al. NSD1 is essential for early post-implantation development and has a catalytically active SET domain. The EMBO journal 2003; 22: 3153-63.
137. Bell O, Wirbelauer C, Hild M, et al. Localized H3K36 methylation states define histone H4K16 acetylation during transcriptional elongation in Drosophila. The EMBO journal 2007; 26: 4974-84.
138. Stabell M, Larsson J, Aalen RB, Lambertsson A. Drosophila dSet2 functions in H3-K36 methylation and is required for development. Biochemical and biophysical research communications 2007; 359: 784-9.
139. Li Y, Trojer P, Xu CF, et al. The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate. The Journal of biological chemistry 2009; 284: 34283-95.
140. Al Sarakbi W, Sasi W, Jiang WG, Roberts T, Newbold RF, Mokbel K. The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters. BMC cancer 2009; 9: 290.
141. Duns G, van den Berg E, van Duivenbode I, et al. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer research 2010; 70: 4287-91.
142. Wang GG, Cai L, Pasillas MP, Kamps MP. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nature cell biology 2007; 9: 804-12.
143. Leventopoulos G, Kitsiou-Tzeli S, Kritikos K, et al. A clinical study of Sotos syndrome patients with review of the literature. Pediatric neurology 2009; 40: 357-64.
144. Kurotaki N, Imaizumi K, Harada N, et al. Haploinsufficiency of NSD1 causes Sotos syndrome. Nature genetics 2002; 30: 365-6.
145. Giannattasio M, Lazzaro F, Plevani P, Muzi-Falconi M. The DNA damage checkpoint response requires histone H2B ubiquitination by Rad6-Bre1 and H3 methylation by Dot1. The Journal of biological chemistry 2005; 280: 9879-86.
146. San-Segundo PA, Roeder GS. Role for the silencing protein Dot1 in meiotic checkpoint control. Molecular biology of the cell 2000; 11: 3601-15.
147. Wysocki R, Javaheri A, Allard S, Sha F, Cote J, Kron SJ. Role of Dot1-dependent histone H3 methylation in G1 and S phase DNA damage checkpoint functions of Rad9. Molecular and cellular biology 2005; 25: 8430-43.
148. Schulze JM, Jackson J, Nakanishi S, et al. Linking cell cycle to histone modifications: SBF and H2B monoubiquitination machinery and cell-cycle regulation of H3K79 dimethylation. Molecular cell 2009; 35: 626-41.
149. Steger DJ, Lefterova MI, Ying L, et al. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Molecular and cellular biology 2008; 28: 2825-39.
150. Schubeler D, MacAlpine DM, Scalzo D, et al. The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes & development 2004; 18: 1263-71.
151. Frederiks F, Tzouros M, Oudgenoeg G, et al. Nonprocessive methylation by Dot1 leads to functional redundancy of histone H3K79 methylation states. Nature structural & molecular biology 2008; 15: 550-7.
152. Min J, Feng Q, Li Z, Zhang Y, Xu RM. Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase. Cell 2003; 112: 711-23.
153. Jones B, Su H, Bhat A, et al. The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure. PLoS genetics 2008; 4: e1000190.
154. Shanower GA, Muller M, Blanton JL, Honti V, Gyurkovics H, Schedl P. Characterization of the grappa gene, the Drosophila histone H3 lysine 79 methyltransferase. Genetics 2005; 169: 173-84.
155. Sawada K, Yang Z, Horton JR, Collins RE, Zhang X, Cheng X. Structure of the conserved core of the yeast Dot1p, a nucleosomal histone H3 lysine 79 methyltransferase. The Journal of biological chemistry 2004; 279: 43296-306.
156. Zhang W, Hayashizaki Y, Kone BC. Structure and regulation of the mDot1 gene, a mouse histone H3 methyltransferase. The Biochemical journal 2004; 377: 641-51.
157. Ng HH, Xu RM, Zhang Y, Struhl K. Ubiquitination of histone H2B by Rad6 is required for efficient Dot1-mediated methylation of histone H3 lysine 79. The Journal of biological chemistry 2002; 277: 34655-7.
158. Briggs SD, Xiao T, Sun ZW, et al. Gene silencing: trans-histone regulatory pathway in chromatin. Nature 2002; 418: 498.
159. Wood A, Krogan NJ, Dover J, et al. Bre1, an E3 ubiquitin ligase required for recruitment and substrate selection of Rad6 at a promoter. Molecular cell 2003; 11: 267-74.
160. Shahbazian MD, Zhang K, Grunstein M. Histone H2B ubiquitylation controls processive methylation but not monomethylation by Dot1 and Set1. Molecular cell 2005; 19: 271-7.
161. Kouskouti A, Talianidis I. Histone modifications defining active genes persist after transcriptional and mitotic inactivation. The EMBO journal 2005; 24: 347-57.
162. Krogan NJ, Dover J, Wood A, et al. The Paf1 complex is required for histone H3 methylation by COMPASS and Dot1p: linking transcriptional elongation to histone methylation. Molecular cell 2003; 11: 721-9.
163. Barry ER, Corry GN, Rasmussen TP. Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development. Expert opinion on therapeutic targets 2010; 14: 405-18.
164. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer cell 2011; 19: 17-30.
165. Bhaumik SR, Smith E, Shilatifard A. Covalent modifications of histones during development and disease pathogenesis. Nature structural & molecular biology 2007; 14: 1008-16.
166. Kim KC, Geng L, Huang S. Inactivation of a histone methyltransferase by mutations in human cancers. Cancer research 2003; 63: 7619-23.
167. Rougeulle C, Chaumeil J, Sarma K, et al. Differential histone H3 Lys-9 and Lys-27 methylation profiles on the X chromosome. Molecular and cellular biology 2004; 24: 5475-84.
168. Maison C, Bailly D, Peters AH, et al. Higher-order structure in pericentric heterochromatin involves a distinct pattern of histone modification and an RNA component. Nature genetics 2002; 30: 329-34.
169. Mermoud JE, Popova B, Peters AH, Jenuwein T, Brockdorff N. Histone H3 lysine 9 methylation occurs rapidly at the onset of random X chromosome inactivation. Current biology: CB 2002; 12: 247-51.
170. Peters AH, Mermoud JE, O'Carroll D, et al. Histone H3 lysine 9 methylation is an epigenetic imprint of facultative heterochromatin. Nature genetics 2002; 30: 77-80.
171. Boggs BA, Cheung P, Heard E, Spector DL, Chinault AC, Allis CD. Differentially methylated forms of histone H3 show unique association patterns with inactive human X chromosomes. Nature genetics 2002; 30: 73-6.
172. Noma K, Allis CD, Grewal SI. Transitions in distinct histone H3 methylation patterns at the heterochromatin domain boundaries. Science 2001; 293: 1150-5.
173. Litt MD, Simpson M, Gaszner M, Allis CD, Felsenfeld G. Correlation between histone lysine methylation and developmental changes at the chicken beta-globin locus. Science 2001; 293: 2453-5.
174. Tachibana M, Ueda J, Fukuda M, et al. Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9. Genes & development 2005; 19: 815-26.
175. Peters AH, Kubicek S, Mechtler K, et al. Partitioning and plasticity of repressive histone methylation states in mammalian chromatin. Molecular cell 2003; 12: 1577-89.
176. Rea S, Eisenhaber F, O'Carroll D, et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 2000; 406: 593-9.
177. Sharma GG, Hwang KK, Pandita RK, et al. Human heterochromatin protein 1 isoforms HP1(Hsalpha) and HP1(Hsbeta) interfere with hTERT-telomere interactions and correlate with changes in cell growth and response to ionizing radiation. Molecular and cellular biology 2003; 23: 8363-76.
178. Aagaard L, Laible G, Selenko P, et al. Functional mammalian homologues of the Drosophila PEV-modifier Su(var)3-9 encode centromere-associated proteins which complex with the heterochromatin component M31. The EMBO journal 1999; 18: 1923-38.
179. Moore BP. Biological and clinical significance of differences between RBC membrane (Rh) and non membrane (ABH, MN, P) antigenic sites. Revue francaise de transfusion et immunohematologie 1976; 19: 629-30.
180. Tachibana M, Sugimoto K, Nozaki M, et al. G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes & development 2002; 16: 1779-91.
181. Dong KB, Maksakova IA, Mohn F, et al. DNA methylation in ES cells requires the lysine methyltransferase G9a but not its catalytic activity. The EMBO journal 2008; 27: 2691-701.
182. Kondo Y, Shen L, Ahmed S, Boumber Y, Sekido Y, Haddad BR, Issa JP. Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PloS one 2008; 3: e2037.
183. Wu H, Min J, Lunin VV, et al. Structural biology of human H3K9 methyltransferases. PloS one 2010; 5: e8570.
184. Rathert P, Dhayalan A, Murakami M, et al. Protein lysine methyltransferase G9a acts on non-histone targets. Nature chemical biology 2008; 4: 344-6.
185. Chin HG, Pradhan M, Esteve PO, Patnaik D, Evans TC, Jr., Pradhan S. Sequence specificity and role of proximal amino acids of the histone H3 tail on catalysis of murine G9A lysine 9 histone H3 methyltransferase. Biochemistry 2005; 44: 12998-3006.
186. Fritsch L, Robin P, Mathieu JR, et al. A subset of the histone H3 lysine 9 methyltransferases Suv39h1, G9a, GLP, and SETDB1 participate in a multimeric complex. Molecular cell 2010; 37: 46-56.
187. Ueda J, Tachibana M, Ikura T, Shinkai Y. Zinc finger protein Wiz links G9a/GLP histone methyltransferases to the co-repressor molecule CtBP. The Journal of biological chemistry 2006; 281: 20120-8.
188. Wang H, An W, Cao R, et al. mAM facilitates conversion by ESET of dimethyl to trimethyl lysine 9 of histone H3 to cause transcriptional repression. Molecular cell 2003; 12: 475-87.
189. Li H, Rauch T, Chen ZX, Szabo PE, Riggs AD, Pfeifer GP. The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells. The Journal of biological chemistry 2006; 281: 19489-500.
190. O'Geen H, Squazzo SL, Iyengar S, et al. Genome-wide analysis of KAP1 binding suggests autoregulation of KRAB-ZNFs. PLoS genetics 2007; 3: e89.
191. Sripathy SP, Stevens J, Schultz DC. The KAP1 corepressor functions to coordinate the assembly of de novo HP1-demarcated microenvironments of heterochromatin required for KRAB zinc finger protein-mediated transcriptional repression. Molecular and cellular biology 2006; 26: 8623-38.
192. Takada I, Mihara M, Suzawa M, et al. A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation. Nature cell biology 2007; 9: 1273-85.
193. Wang C, Rauscher FJ, 3rd, Cress WD, Chen J. Regulation of E2F1 function by the nuclear corepressor KAP1. The Journal of biological chemistry 2007; 282: 29902-9.
194. Loyola A, Tagami H, Bonaldi T, et al. The HP1alpha-CAF1-SetDB1-containing complex provides H3K9me1 for Suv39-mediated K9me3 in pericentric heterochromatin. EMBO reports 2009; 10: 769-75.
195. Brower-Toland B, Riddle NC, Jiang H, Huisinga KL, Elgin SC. Multiple SET methyltransferases are required to maintain normal heterochromatin domains in the genome of Drosophila melanogaster. Genetics 2009; 181: 1303-19.
196. Yoon J, Lee KS, Park JS, Yu K, Paik SG, Kang YK. dSETDB1 and SU(VAR)3-9 sequentially function during germline-stem cell differentiation in Drosophila melanogaster. PloS one 2008; 3: e2234.
197. Lee J, Hagerty S, Cormier KA, et al. Monoallele deletion of CBP leads to pericentromeric heterochromatin condensation through ESET expression and histone H3 (K9) methylation. Human molecular genetics 2008; 17: 1774-82.
198. Barski A, Cuddapah S, Cui K, et al. High-resolution profiling of histone methylations in the human genome. Cell 2007; 129: 823-37.
199. Cheng X, Blumenthal RM. Coordinated chromatin control: structural and functional linkage of DNA and histone methylation. Biochemistry 2010; 49: 2999-3008.
200. Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, Liang G, Jones PA. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer research 2002; 62: 6456-61.
201. Huang J, Dorsey J, Chuikov S, et al. G9a and Glp methylate lysine 373 in the tumor suppressor p53. The Journal of biological chemistry 2010; 285: 9636-41.
202. Park YS, Jin MY, Kim YJ, Yook JH, Kim BS, Jang SJ. The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Annals of surgical oncology 2008; 15: 1968-76.
203. Pogribny IP, Tryndyak VP, Muskhelishvili L, Rusyn I, Ross SA. Methyl deficiency, alterations in global histone modifications, and carcinogenesis. The Journal of nutrition 2007; 137: 216S-22S.
204. Cloos PA, Christensen J, Agger K, et al. The putative oncogene GASC1 demethylates tri-and dimethylated lysine 9 on histone H3. Nature 2006; 442: 307-11.
205. Yang ZQ, Imoto I, Fukuda Y, et al. Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines. Cancer research 2000; 60: 4735-9.
206. Wu J, Liu S, Liu G, Dombkowski A, Abrams J, Martin-Trevino R, Wicha MS, Ethier SP, Yang ZQ. Identification and functional analysis of 9p24 amplified genes in human breast cancer. Oncogene 2012; 31: 333-41.
207. Liu G, Bollig-Fischer A, Kreike B, et al. Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene 2009; 28: 4491-500.
208. Hu N, Wang C, Hu Y, et al. Genome-wide association study in esophageal cancer using GeneChip mapping 10K array. Cancer research 2005; 65: 2542-6.
209. Yang ZQ, Imoto I, Pimkhaokham A, et al. A novel amplicon at 9p23-24 in squamous cell carcinoma of the esophagus that lies proximal to GASC1 and harbors NFIB. Japanese journal of cancer research: Gann 2001; 92: 423-8.
210. Bernstein BE, Mikkelsen TS, Xie X, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006; 125: 315-26.
211. Simon JA, Kingston RE. Mechanisms of polycomb gene silencing: knowns and unknowns. Nature reviews. Molecular cell biology 2009; 10: 697-708.
212. Margueron R, Li G, Sarma K, et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Molecular cell 2008; 32: 503-18.
213. Shen X, Liu Y, Hsu YJ, et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Molecular cell 2008; 32: 491-502.
214. Schwartz YB, Pirrotta V. Polycomb silencing mechanisms and the management of genomic programmes. Nature reviews. Genetics 2007; 8: 9-22.
215. Margueron R, Justin N, Ohno K, et al. Role of the polycomb protein EED in the propagation of repressive histone marks. Nature 2009; 461: 762-7.
216. Pasini D, Bracken AP, Jensen MR, Lazzerini Denchi E, Helin K. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. The EMBO journal 2004; 23: 4061-71.
217. Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EEDEZH2 complex. Molecular cell 2004; 15: 57-67.
218. Li G, Margueron R, Ku M, Chambon P, Bernstein BE, Reinberg D. Jarid2 and PRC2, partners in regulating gene expression. Genes & development 2010; 24: 368-80.
219. Pasini D, Cloos PA, Walfridsson J, Olsson L, Bukowski JP, Johansen JV, Bak M, Tommerup N, Rappsilber J, Helin K. JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells. Nature 2010; 464: 306-10.
220. Peng JC, Valouev A, Swigut T, et al. Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells. Cell 2009; 139: 1290-302.
221. Shen X, Kim W, Fujiwara Y, et al. Jumonji modulates polycomb activity and self-renewal versus differentiation of stem cells. Cell 2009; 139: 1303-14.
222. Cao R, Wang H, He J, et al. Role of hPHF1 in H3K27 methylation and Hox gene silencing. Molecular and cellular biology 2008; 28: 1862-72.
223. Sarma K, Margueron R, Ivanov A, Pirrotta V, Reinberg D. Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in vivo. Molecular and cellular biology 2008; 28: 2718-31.
224. Walker E, Chang WY, Hunkapiller J, et al. Polycomb-like 2 associates with PRC2 and regulates transcriptional networks during mouse embryonic stem cell self-renewal and differentiation. Cell stem cell 2010; 6: 153-66.
225. Zhang Z, Jones A, Sun CW, et al. PRC2 complexes with JARID2, MTF2, and esPRC2p48 in ES cells to modulate ES cell pluripotency and somatic cell reprogramming. Stem cells 2011; 29: 229-40.
226. Boulay G, Rosnoblet C, Guerardel C, Angrand PO, Leprince D. Functional characterization of human Polycomb-like 3 isoforms identifies them as components of distinct EZH2 protein complexes. The Biochemical journal 2011; 434: 333-42.
227. Wang S, Robertson GP, Zhu J. A novel human homologue of Drosophila polycomblike gene is up-regulated in multiple cancers. Gene 2004; 343: 69-78.
228. Landeira D, Sauer S, Poot R, et al. Jarid2 is a PRC2 component in embryonic stem cells required for multi-lineage differentiation and recruitment of PRC1 and RNA Polymerase II to developmental regulators. Nature cell biology 2010; 12: 618-24.
229. Herz HM, Shilatifard A. The JARID2-PRC2 duality. Genes & development 2010; 24: 857-61.
230. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002; 298: 1039-43.
231. Stock JK, Giadrossi S, Casanova M, et al. Ring1-mediated ubiquitination of H2A restrains poised RNA polymerase II at bivalent genes in mouse ES cells. Nature cell biology 2007; 9: 1428-35.
232. Francis NJ, Kingston RE, Woodcock CL. Chromatin compaction by a polycomb group protein complex. Science 2004; 306: 1574-7.
233. Wang H, Wang L, Erdjument-Bromage H, et al. Role of histone H2A ubiquitination in Polycomb silencing. Nature 2004; 431: 873-8.
234. Ringrose L, Rehmsmeier M, Dura JM, Paro R. Genome-wide prediction of Polycomb/Trithorax response elements in Drosophila melanogaster. Developmental cell 2003; 5: 759-71.
235. Sing A, Pannell D, Karaiskakis A, et al. A vertebrate Polycomb response element governs segmentation of the posterior hindbrain. Cell 2009; 138: 885-97.
236. Vella P, Barozzi I, Cuomo A, Bonaldi T, Pasini D. Yin Yang 1 extends the Myc-related transcription factors network in embryonic stem cells. Nucleic acids research 2011.
237. Mendenhall EM, Koche RP, Truong T, et al. GC-rich sequence elements recruit PRC2 in mammalian ES cells. PLoS genetics 2010; 6: e1001244.
238. Woo CJ, Kharchenko PV, Daheron L, Park PJ, Kingston RE. A region of the human HOXD cluster that confers polycomb-group responsiveness. Cell 2010; 140: 99-110.
239. Hansen KH, Bracken AP, Pasini D, et al. A model for transmission of the H3K27me3 epigenetic mark. Nature cell biology 2008; 10: 1291-300.
240. Schuettengruber B, Cavalli G. Recruitment of polycomb group complexes and their role in the dynamic regulation of cell fate choice. Development 2009; 136: 3531-42.
241. Cui K, Zang C, Roh TY, et al. Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate of bivalent genes during differentiation. Cell stem cell 2009; 4: 80-93.
242. Piunti A, Pasini D. Epigenetic factors in cancer development: polycomb group proteins. Future oncology 2011; 7: 57-75.
243. Lan F, Bayliss PE, Rinn JL, et al. A histone H3 lysine 27 demethylase regulates animal posterior development. Nature 2007; 449: 689-94.
244. Lee MG, Villa R, Trojer P, et al. Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination. Science 2007; 318: 447-50.
245. Agger K, Cloos PA, Christensen J, et al. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 2007; 449: 731-4.
246. Barradas M, Anderton E, Acosta JC, Li S, Banito A, Rodriguez-Niedenfuhr M, Maertens G, Banck M, Zhou MM, Walsh MJ, Peters G, Gil J. Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes & development 2009; 23: 1177-82.
247. Agger K, Cloos PA, Rudkjaer L, et al. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4AARF locus in response to oncogene-and stress-induced senescence. Genes & development 2009; 23: 1171-6.
248. Bracken AP, Kleine-Kohlbrecher D, Dietrich N, et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes & development 2007; 21: 525-30.
249. Pasini D, Malatesta M, Jung HR, et al. Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes. Nucleic acids research 2010; 38: 4958-69.
250. van Haaften G, Dalgliesh GL, et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nature genetics 2009; 41: 521-3.
251. Anderton JA, Bose S, Vockerodt M, et al. The H3K27me3 demethylase, KDM6B, is induced by Epstein-Barr virus and overexpressed in Hodgkin's Lymphoma. Oncogene 2011; 30: 2037-43.
252. Xiang Y, Zhu Z, Han G, Lin H, Xu L, Chen CD. JMJD3 is a histone H3K27 demethylase. Cell research 2007; 17: 850-7.
253. Schotta G, Lachner M, Sarma K, et al. A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes & development 2004; 18: 1251-62.
254. Kourmouli N, Jeppesen P, Mahadevhaiah S, et al. Heterochromatin and tri-methylated lysine 20 of histone H4 in animals. Journal of cell science 2004; 117: 2491-501.
255. Nishioka K, Rice JC, Sarma K, et al. PR-Set7 is a nucleosomespecific methyltransferase that modifies lysine 20 of histone H4 and is associated with silent chromatin. Molecular cell 2002; 9: 1201-13.
256. Couture JF, Collazo E, Brunzelle JS, Trievel RC. Structural and functional analysis of SET8, a histone H4 Lys-20 methyltransferase. Genes & development 2005; 19: 1455-65.
257. Xiao B, Jing C, Kelly G, et al. Specificity and mechanism of the histone methyltransferase Pr-Set7. Genes & development 2005; 19: 1444-54.
258. Fang J, Feng Q, Ketel CS, et al. Purification and functional characterization of SET8, a nucleosomal histone H4-lysine 20-specific methyltransferase. Current biology: CB 2002; 12: 1086-99.
259. Liu W, Tanasa B, Tyurina OV, et al. PHF8 mediates histone H4 lysine 20 demethylation events involved in cell cycle progression. Nature 2010; 466: 508-12.
260. Qi HH, Sarkissian M, Hu GQ, et al. Histone H4K20/H3K9 demethylase PHF8 regulates zebrafish brain and craniofacial development. Nature 2010; 466: 503-7.
261. Houston SI, McManus KJ, Adams MM, et al. Catalytic function of the PR-Set7 histone H4 lysine 20 monomethyltransferase is essential for mitotic entry and genomic stability. The Journal of biological chemistry 2008; 283: 19478-88.
262. Rice JC, Nishioka K, Sarma K, Steward R, Reinberg D, Allis CD. Mitotic-specific methylation of histone H4 Lys 20 follows increased PR-Set7 expression and its localization to mitotic chromosomes. Genes & development 2002; 16: 2225-30.
263. Huen MS, Sy SM, van Deursen JM, Chen J. Direct interaction between SET8 and proliferating cell nuclear antigen couples H4-K20 methylation with DNA replication. The Journal of biological chemistry 2008; 283: 11073-7.
264. Jorgensen S, Elvers I, Trelle MB, et al. The histone methyltransferase SET8 is required for S-phase progression. The Journal of cell biology 2007; 179: 1337-45.
265. Tardat M, Murr R, Herceg Z, Sardet C, Julien E. PR-Set7-dependent lysine methylation ensures genome replication and stability through S phase. The Journal of cell biology 2007; 179: 1413-26.
266. Oda H, Hubner MR, Beck DB, et al. Regulation of the histone H4 monomethylase PR-Set7 by CRL4(Cdt2)-mediated PCNAdependent degradation during DNA damage. Molecular cell 2010; 40: 364-76.
267. Tardat M, Brustel J, Kirsh O, et al. The histone H4 Lys 20 methyltransferase PR-Set7 regulates replication origins in mammalian cells. Nature cell biology 2010; 12: 1086-93.
268. Centore RC, Havens CG, Manning AL, et al. CRL4(Cdt2)-mediated destruction of the histone methyltransferase Set8 prevents premature chromatin compaction in S phase. Molecular cell 2010; 40: 22-33.
269. Oda H, Okamoto I, Murphy N, et al. Monomethylation of histone H4-lysine 20 is involved in chromosome structure and stability and is essential for mouse development. Molecular and cellular biology 2009; 29: 2278-95.
270. Van Den Broeck A, Brambilla E, et al. Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 2008; 14: 7237-45.
271. Tryndyak VP, Kovalchuk O, Pogribny IP. Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins. Cancer biology & therapy 2006; 5: 65-70.
272. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature genetics 2005; 37: 391-400.
273. Kwon MJ, Kim SS, Choi YL, et al. Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications. Carcinogenesis 2010; 31: 974-83.
274. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
275. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-92.
276. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nature reviews. Cancer 2006; 6: 846-56.
277. Garagnani P, Pirazzini C, Franceschi C. Colorectal Cancer Microenvirnoment: between Nutrition, Gut Microbiota, Inflammation and Epigenetics. Curr Pharm Des 2013; 19(4): 765-78.
278. Andreoli F, Barbosa AJM, Parenti MD, Del Rio A. Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Curr Pharm Des 201; 19(4): 578-613.
279. Jain N, Rossi A, Garcia-Manero G. Epigenetic therapy of leukemia: An update. The international journal of biochemistry & cell biology 2009; 41: 72-80.
280. Smith LT, Otterson GA, Plass C. Unraveling the epigenetic code of cancer for therapy. Trends in genetics: TIG 2007; 23: 449-56.